DAFTAR PUSTAKA

Alharbi, K. S., Almalki, W. H., Makeen, H. A., Albratty, M., Meraya, A. M., Nagraik, R., Sharma, A., Kumar, D., Chellappan, D. K., Singh, S. K., Dua, K., & Gupta, G. (2022). Role of Medicinal plant-derived Nutraceuticals as a potential target for the treatment of breast cancer. *Journal of Food Biochemistry*, *46*(12), 1–18. https://doi.org/10.1111/jfbc.14387

Allison, E., Edirimanne, S., & Matthews, J. (2023). Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers : A Systematic Review and Meta-Analysis. *Oncology and Therapy*, *11*(1), 27–48. https://doi.org/10.1007/s40487-022-00214-3

Aramini, B., Masciale, V., Grisendi, G., Banchelli, F., D'Amico, R., Maiorana, A., Morandi, U., Dominici, M., & Haider, K. H. (2021). Cancer stem cells and macrophages: Molecular connections and future perspectives against cancer. *Oncotarget*, *12*(3), 230–250. https://doi.org/10.18632/ONCOTARGET.27870

Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast*, *66*(June), 15–23. https://doi.org/10.1016/j.breast.2022.08.010

Arole, V., Nitta, H., Wei, L., Shen, T., Parwani, A. V, & Li, Z. (2021). M2 tumor - associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple - negative breast carcinoma. *Breast Cancer Research and Treatment*, *0123456789*. https://doi.org/10.1007/s10549-021-06260-1

Banerjee, K., Kerzel, T., Bekkhus, T., Arne, O., Squadrito, M. L., Banerjee, K., Kerzel, T., Bekkhus, T., Ferreira, S. D. S., & Wallmann, T. (2023). *Report VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells ll VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells*. https://doi.org/10.1016/j.celrep.2023.113507

Barrios, C. H. (2022). Global challenges in breast cancer detection and treatment. *Breast*, *62*(S1), S3–S6. https://doi.org/10.1016/j.breast.2022.02.003

Basak, U., Sarkar, T., Mukherjee, S., Chakraborty, S., Dutta, A., Dutta, S., Nayak, D., Kaushik, S., Das, T., & Sa, G. (2023). Tumor-associated macrophages: an effective player of the tumor microenvironment. *Frontiers in Immunology*, *14*(November), 1–22. https://doi.org/10.3389/fimmu.2023.1295257

Bied, M., Ho, W. W., Ginhoux, F., & Blériot, C. (2023). Roles of macrophages in tumor development: a spatiotemporal perspective. *Cellular and Molecular Immunology*, *20*(9), 983–992. https://doi.org/10.1038/s41423-023-01061-6

Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *74*(3), 229–263. https://doi.org/10.3322/caac.21834

Cha, Y. J., & Tam, M. I. I. (2020). *Role of Tumor-Associated Myeloid Cells contribute*.

Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014). Tumor-associated macrophages as major players in the tumor microenvironment. *Cancers*, *6*(3), 1670–1690. https://doi.org/10.3390/cancers6031670

Chen, Y., Klingen, T. A., Aas, H., Wik, E., & Akslen, L. A. (2021). Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer. *Journal of Pathology: Clinical Research*, *7*(5), 517–527. https://doi.org/10.1002/cjp2.226

Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019). Tumor-associated macrophages: An accomplice in solid tumor progression. *Journal of Biomedical Science*, *26*(1), 1–13. https://doi.org/10.1186/s12929-019-0568-z

Delprat, V., & Michiels, C. (2021). A bi-directional dialog between vascular cells and monocytes/macrophages regulates tumor progression. *Cancer and Metastasis Reviews*, *40*(2), 477–500. https://doi.org/10.1007/s10555-021-09958-2

Domínguez-Cejudo, M. A., Gil-Torralvo, A., Cejuela, M., Molina-Pinelo, S., & Salvador Bofill, J. (2023). Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities. *International Journal of Molecular Sciences*, *24*(23). https://doi.org/10.3390/ijms242316771

Fang, C., Cheung, M. Y., Chan, R. C., Poon, I. K., Lee, C., To, C. C., Tsang, J. Y., Li, J., & Tse, G. M. (2024). *Spatial Distribution and Tumor-Infiltrating Lymphocytes in Breast Cancer*.

Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020). Molecular principles of metastasis: a hallmark of cancer revisited. *Signal Transduction and Targeted Therapy*, *5*(1).

https://doi.org/10.1038/s41392-020-0134-x
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H. H., Haydon, R. C., He, T. C., & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes and Diseases*, *5*(2), 77–106. https://doi.org/10.1016/j.gendis.2018.05.001
Firatligil-Yildirir, B., Yalcin-Ozuysal, O., & Nonappa, N. (2023). Recent advances in lab-on-a-chip systems for breast cancer metastasis research. *Nanoscale Advances*, *5*(9), 2375–2393. https://doi.org/10.1039/d2na00823h
Gadde, M., Mehrabi-Dehdezi, M., Debeb, B. G., Woodward, W. A., & Rylander, M. N. (2023). Influence of Macrophages on Vascular Invasion of Inflammatory Breast Cancer Emboli Measured Using an In Vitro Microfluidic Multi-Cellular Platform. *Cancers*, *15*(19). https://doi.org/10.3390/cancers15194883
Gao, J., Liang, Y., & Wang, L. (2022). Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. *Frontiers in Immunology*, *13*(June), 1–12. https://doi.org/10.3389/fimmu.2022.888713
Garvin, S., Oda, H., Gunnar, L., Annelie, A., & Ivan, L. (2018). Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery. *Journal of Cancer Research and Clinical Oncology*, *144*(7), 1253–1263. https://doi.org/10.1007/s00432-018-2646-0
Gwak, J. M., Jang, M. H., Kim, D. Il, Seo, A. N., & Park, S. Y. (2015). Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. *PLoS ONE*, *10*(4), 1–14. https://doi.org/10.1371/journal.pone.0125728
Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. *Cancer Discovery*, *12*(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
Hill, B. S., Sarnella, A., D'Avino, G., & Zannetti, A. (2020). Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. *Seminars in Cancer Biology*, *60*(August 2019), 202–213. https://doi.org/10.1016/j.semcancer.2019.07.028
Homer-vanniasinkam, S., Wheatcroft, S. B., & Ponnambalam, S. (2015). *Scavenger Receptor Structure and Function in Health and Disease*. 178–201. https://doi.org/10.3390/cells4020178
Hourani, T., Holden, J. A., Li, W., Lenzo, J. C., Hadjigol, S., & O'Brien-Simpson, N. M. (2021). Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting. *Frontiers in Oncology*, *11*(December), 1–20. https://doi.org/10.3389/fonc.2021.788365
Huang, X., Cao, J., & Zu, X. (2022). Tumor-associated macrophages: An important player in breast cancer progression. *Thoracic Cancer*, *13*(3), 269–276. https://doi.org/10.1111/1759-7714.14268
Iskandar, I., Padmawati, R. S., Hutajulu, S. H., & Fajrin, M. (2024). Analysis of Presentation Delay in Patients with Advanced Breast Cancer Visiting Dharmais National Cancer Hospital. *Indonesian Journal of Cancer*, *18*(1), 27–31. https://doi.org/10.33371/ijoc.v18i1.1025
Jamiyan, T., & Kuroda, H. (2020). *CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast*. 767–775.
Jeong, H., & Hwang, I. (2019). *Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer*. *22*(1), 38–51.
Kazakova, E., Iamshchikov, P., Larionova, I., & Kzhyshkowska, J. (2023). *Macrophage scavenger receptors : Tumor support and tumor inhibition*. *January*, 1–18. https://doi.org/10.3389/fonc.2022.1096897
Khan, M. U., Azhar, M., Din, U., Khan, I. M., Khan, M. I., Bungau, S., & Shams, S. (2023). *Reprogramming tumor- associated macrophages as a unique approach to target tumor immunotherapy*. *April*, 1–14. https://doi.org/10.3389/fimmu.2023.1166487
Klingen, T. A., Chen, Y., Aas, H., Wik, E., & Akslen, L. A. (2017). Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer. *Human Pathology*, *69*, 72–80. https://doi.org/10.1016/j.humpath.2017.09.001
Krag, D. (2020). Breast Cancer. *Surgical Oncology*, 15–31. https://doi.org/10.1201/9781498712651-4
Laconi, E., Marongiu, F., & DeGregori, J. (2020). Cancer as a disease of old age: changing mutational and microenvironmental landscapes. *British Journal of Cancer*, *122*(7), 943–952. https://doi.org/10.1038/s41416-019-0721-1
Li, Y., Wang, R., & Gao, Q. (2023). The Roles and Targeting of Tumor-Associated Macrophages. *Frontiers in Bioscience - Landmark*, *28*(9). https://doi.org/10.31083/j.fbl2809207
Lin, Y., Xu, J., & Lan, H. (2019). *Tumor-associated macrophages in tumor metastasis : biological roles and clinical therapeutic applications*. *3*, 1–17.
Liu, T., Larionova, I., Litviakov, N., Riabov, V., Zavyalova, M., Tsyganov, M., Buldakov, M., Song, B.,

Moganti, K., Kazantseva, P., Slonimskaya, E., Kremmer, E., Flatley, A., Klüter, H., Cherdyntseva, N., & Kzhyshkowska, J. (2018). Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. *OncoImmunology*, *7*(6). https://doi.org/10.1080/2162402X.2018.1436922

Liu, Y., & Cao, X. (2015). *Immunosuppressive cells in tumor immune escape and metastasis*. https://doi.org/10.1007/s00109-015-1376-x

Mehta, A. K., Kadel, S., Townsend, M. G., Oliwa, M., & Guerriero, J. L. (2021). *Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer*. *12*(April), 1–17. https://doi.org/10.3389/fimmu.2021.643771

Mwafy, S. E., & El-Guindy, D. M. (2020). Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma. *Journal of the Egyptian National Cancer Institute*, *32*(1). https://doi.org/10.1186/s43046-020-0018-8

Ni, C., Yang, L., Xu, Q., Yuan, H., Wang, W., Xia, W., Gong, D., & Zhang, W. (2019). *J o u r n a l o f C a n c e r CD68- and CD163-positive tumor infiltrating macrophages in non-metastatic breast cancer : a retrospective study and meta-analysis*. *10*. https://doi.org/10.7150/jca.33914

Omilian, A. R., Cannioto, R., Mendicino, L., Stein, L., Bshara, W., Qin, B., Bandera, E. V., Zeinomar, N., Abrams, S. I., Hong, C. C., Yao, S., Khoury, T., & Ambrosone, C. B. (2024). CD163+ macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women's Circle of Health Study and the Women's Circle of Health Follow-Up Study. *Breast Cancer Research*, *26*(1), 1–12. https://doi.org/10.1186/s13058-024-01831-8

Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020). Tumor-Associated Macrophages in Tumor Immunity. *Frontiers in Immunology*, *11*(December). https://doi.org/10.3389/fimmu.2020.583084

Pourriahi, R., Omranipour, R., Alipour, S., Hajimaghsoudi, L., Mashoori, N., Kenary, A. Y., Motamedi, M., Tavakol, M., Mohammadzadeh, M., Hessamiazar, S., Shabani, S., Mahmoodi, F., Goodarzi, M. M., & Eslami, B. (2023). Clinical characteristics of breast cancer patients admitted to academic surgical wards in Tehran, Iran: an analytical cross-sectional study. *BMC Women's Health*, *23*(1), 1–8. https://doi.org/10.1186/s12905-023-02637-0

Prihantono, Rusli, R., Christeven, R., & Faruk, M. (2023). Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review. *Ethiopian Journal of Health Sciences*, *33*(3), 515–522. https://doi.org/10.4314/ejhs.v33i3.15

Proietto, M., Crippa, M., Damiani, C., Pasquale, V., Sacco, E., Vanoni, M., & Gilardi, M. (2023). Tumor heterogeneity: preclinical models, emerging technologies, and future applications. *Frontiers in Oncology*, *13*(April), 1–24. https://doi.org/10.3389/fonc.2023.1164535

Puspasari, D., Istiadi, H., & Amarwati, S. (2017). Hubungan Ekspresi Tumor-Associated Macrophages (TAM)/CD68 dengan Status Ekspresi HER2 pada Karsinoma Payudara Invasif. *Media Medika Muda*, *2*(2).

Qiu, S. Q., Waaijer, S. J. H., Zwager, M. C., de Vries, E. G. E., van der Vegt, B., & Schröder, C. P. (2018). Tumor-associated macrophages in breast cancer: Innocent bystander or important player? *Cancer Treatment Reviews*, *70*(August), 178–189. https://doi.org/10.1016/j.ctrv.2018.08.010

Ramos, R. N., Rodriguez, C., Hubert, M., Ardin, M., Treilleux, I., Ries, C. H., Lavergne, E., Chabaud, S., Colombe, A., Trédan, O., Guedes, H. G., Laginha, F., Richer, W., Piaggio, E., Barbuto, J. A. M., Caux, C., Ménétrier-Caux, C., & Bendriss-Vermare, N. (2020). CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. *Clinical and Translational Immunology*, *9*(2). https://doi.org/10.1002/cti2.1108

Respati, E. A. R. I. (2023). *Universitas Gadjah Mada, 2023 | Diunduh dari http://etd.repository.ugm.ac.id/*. *43*(1), 97–102.

Sari, S., Özdemir, Ç., & Çilekar, M. (2022). The relationship of tumour-associated macrophages (CD68, CD163, CD11c) and cancer stem cell (CD44) markers with prognostic parameters in breast carcinomas. *Polish Journal of Pathology*, *73*(4), 299–309. https://doi.org/10.5114/pjp.2022.125424

Setyawan, I. B., Kurnia, D., Setiaji, K., Anwar, S. L., Purwanto, D. J., Azhar, Y., Budijitno, S., Suprabawati, D. G. A., Priyono, S. H., Siregar, B. A., Indriawan, R., Tripriadi, E. S., Umar, M., Pieter, J. S., Yarso, K. Y., Hermansyah, D., Wibisana, I. G., Harahap, W. A., Gautama, W., & Achmad, D. (2023). Sociodemographic disparities associated with advanced stages and distant metastatic breast cancers at diagnosis in Indonesia: a cross-sectional study. *Annals of Medicine & Surgery*, *85*(9), 4211–4217. https://doi.org/10.1097/ms9.0000000000001030

Setyawati, Y., Rahmawati, Y., Widodo, I., Ghozali, A., & Purnomosari, D. (2018). The association

between molecular subtypes of breast cancer with histological grade and lymph node metastases in Indonesian woman. *Asian Pacific Journal of Cancer Prevention*, *19*(5), 1263–1268. https://doi.org/10.22034/APJCP.2018.19.5.1263

Siregar, K. B., & Al Anas, M. (2023). Unveiling bone metastasis: Exploring histological subtypes of breast cancer in Indonesia's tertiary referral hospital. *Cancer Treatment and Research Communications*, *37*(September), 100764. https://doi.org/10.1016/j.ctarc.2023.100764

Stavrou, M., & Constantinidou, A. (2024). Tumor associated macrophages in breast cancer progression: implications and clinical relevance. *Frontiers in Immunology*, *15*(July), 1–7. https://doi.org/10.3389/fimmu.2024.1441820

Su, P., Li, O. U., Ke, K. U. N., Jiang, Z., & Wu, J. (2024). *Targeting tumor - associated macrophages : Critical players in tumor progression and therapeutic strategies (Review)*. 1–21. https://doi.org/10.3892/ijo.2024.5648

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660

Surakasula, A., Nagarjunapu, G., & Raghavaiah, K. (2014). A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management. *Journal of Research in Pharmacy Practice*, *3*(1), 12. https://doi.org/10.4103/2279-042x.132704

Syaifudin, A. (2020). *Correlation between expression on histopathological grading , metastasis , survival overall (SO) and disease free survival (DFS) on women breast cancer*. *52*(3), 243–250.

Tan, Y., Wang, M., Zhang, Y., Ge, S., Zhong, F., Xia, G., & Sun, C. (2021). Tumor-Associated Macrophages: A Potential Target for Cancer Therapy. *Frontiers in Oncology*, *11*(June), 1–17. https://doi.org/10.3389/fonc.2021.693517

Wiratama, P. A., & Sandhika, W. (2020). Ratio of CD68/CD163 in Breast Carcinoma with and without Axillary Lymph Node Metastatic. *Folia Medica Indonesiana*, *56*(1), 19. https://doi.org/10.20473/fmi.v56i1.18446

Wu, D., Liu, X., Mu, J., Yang, J., Wu, F., & Zhou, H. (2022). Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers. *Biomolecules*, *12*(3). https://doi.org/10.3390/biom12030392

Ye, J., Wang, X., Shi, J., Yin, X., Chen, C., Chen, Y., Wu, H., & Jiong, S. (2021). *Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer*. *12*. https://doi.org/10.7150/jca.47566

Yu, Z., Zou, J., & Xu, F. (2024). Tumor-associated macrophages affect the treatment of lung cancer. *Heliyon*, *10*(7), e29332. https://doi.org/10.1016/j.heliyon.2024.e29332

Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024). Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. *Signal Transduction and Targeted Therapy*, *9*(1), 1–36. https://doi.org/10.1038/s41392-024-01848-7

Zheng, W., Marini, W., Murakami, K., Sotov, V., Butler, M., Gorrini, C., Ohashi, P. S., & Reedijk, M. (2024). Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy. *Nature Communications*, *15*(1), 8514. https://doi.org/10.1038/s41467-024-52553-6

Zhong, X., Zhang, H., Zhu, Y., Liang, Y., Yuan, Z., Li, J., Li, J., Li, X., Jia, Y., He, T., Zhu, J., Sun, Y., Jiang, W., Zhang, H., Wang, C., & Ke, Z. (2020). Circulating tumor cells in cancer patients: Developments and clinical applications for immunotherapy. *Molecular Cancer*, *19*(1), 1–13. https://doi.org/10.1186/s12943-020-1141-9

LAMPIRAN 1

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari..,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 1045/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 28 Nopember 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24110965	No Sponsor	
Peneliti Utama	**dr. Muhammad Jauhari, Sp.B**	Sponsor	
Judul Peneliti	HUBUNGAN EKSPRESI TUMOR ASSOCIATED MACROPHAGE (TAM) DENGAN KEJADIAN METASTASIS KANKER PAYUDARA		
No Versi Protokol	**1**	Tanggal Versi	**22 Nopember 2024**
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohursodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **28 Nopember 2024** sampai **28 Nopember 2025**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	**Prof. dr. Muh Nasrum Massi,PhD,SpMK, Subsp. Bakt(K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	**dr. Firdaus Hamid, PhD, SpMK(K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

LAMPIRAN 2

GeneTex Datasheet

CD163 antibody

Cat. No. GTX35248

Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Application	WB, IHC-P, IHC-Fr
Reactivity	Human, Mouse, Rat, Guinea pig

Package
100 µg

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	Assay dependent
IHC-P	1: 100-600
IHC-Fr	Assay dependent

Not tested in other applications.

Calculated MW	125 kDa. (Note)

PROPERTIES

Form	Liquid
Buffer	10mM PBS
Preservative	0.02% Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Concentration	0.5 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen	KLH conjugated synthetic peptide derived from human CD163.
Purification	Purified by antigen-affinity chromatography
Conjugation	Unconjugated
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption. Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

For full product information, images and publications, please visit our website.

GeneTex, Inc. (North America)
1-877-436-3839 (Toll-free) 1-949-309-2888 sales@genetex.com

GeneTex International Corporation (Global)
886-3-6208988 886-3-6208989 intlsales@genetex.com

© 2018 GeneTex Inc. All rights reserved.

DATA IMAGES



GTX35248 IHC-Fr Image

IHC-Fr analysis of mouse skin tissue using GTX35248 CD163 antibody.
Dilution : 1:100



GTX35248 WB Image

WB analysis of rat lung tissue lysate using GTX35248 CD163 antibody.
Dilution : 1:500



GTX35248 IHC-P Image

IHC-P analysis of mouse stomach tissue using GTX35248 CD163 antibody.
Dilution : 2.5µg/ml

GTX35248 WB Image

WB analysis of guniea pig lymph (Lane 1), rat brain (Lane 2), mouse stomach (Lane 3), rat rectum (Lane 4), human gallbladder (Lane 5), human lung cancer (Lane 6) tissue lysates using GTX35248 CD163 antibody.
Dilution : 0.5µg/ml

For full product information, images and publications, please visit our website.

GeneTex, Inc. (North America)
1-877-436-3839 (Toll-free) 1-949-309-2888 sales@genetex.com

GeneTex International Corporation (Global)
886-3-6208988 886-3-6208989 infoasia@genetex.com

© 2018 GeneTex Inc. All rights reserved.

Lampiran 3

No	Nama	Umur	Status menopause	Grading	No. RM	Nomor PA	Hasil PA	Foto Thoraks	USG Abdomen	Metastasis lain	Ekpresi TAM	Staging/Stadium	ER	PR	HER2
1	MR	65	post menopause	Grade 3	217074	HUH24.270	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	metastasis Pleura			Tinggi	IV	positif	positif	positif
2	SH	54	post menopause	Grade 1	97094	HUH24.234	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	negatif	positif
3	HAR	50	Pre menopause	Grade 2	216712	HUH24.211	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE		Metastasis Hepar		Tinggi	IV	negatif	negatif	positif
4	RS	41	pre menopause	Grade 1	218301	HUH24.208	ADENOCARCINOMA MUSINOSUM,	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	positif
5	MS	52	Pre menopause	Grade 3	216176	HUH24.202	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE, MULTIPLE HIGH GRADE DUCTAL CARCINOMA IN SITU		Metastasis Hepar		Tinggi	IV	positif	positif	negatif
6	PH	50	pre menopause	Grade 3	215216	HUH24.043	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	negatif	negatif	positif
7	IR	35	pre menopause	Grade 2	190937	HUH24.216	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE DENGAN MILLER PAYNE		Metastasis Hepar		Tinggi	IV	negatif	negatif	positif
8	AM	49	pre menopause	Grade 3	213955	HUH.23.1387	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE,	Tidak Metastasis	Tidak Metastasis		Tinggi	III B	positif	positif	positif
9	FA	57	post menopause	Grade 2	212579	HUH23.1272	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	negatif	negatif	positif
10	RS	54	post menopause	grade 2	212185	HUH23.1239	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	negatif	negatif	positif
11	AI	42	pre menopause	grade 1	127846	HUH.23.1232	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE			Metastasis Otak	Tinggi	IV	negatif	negatif	positif
12	SM	61	post menopause	grade 3	212055	HUH23.1216	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIA	negatif	negatif	negatif
13	SA	66	post menopause	grade 3	212038	HUH23.1209	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru	Metastasis Hepar		Tinggi	IV	negatif	negatif	positif
14	DM	56	post menopause	grade 2	208593	HUH23.1141	INVASIVE BREAST CARCINOMA NON SPECIAL TYPE,	Tidak Metastasis	Tidak Metastasis		Rendah	II B	positif	positif	negatif
15	MI	35	Pre menopause	grade 2	208213	HUH.23.987	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE, FOKUS DUCTAL CARCINOMA IN SITU MAMMAE DENGAN COMEDO NECROSIS	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	negatif
16	SY	40	Pre menopause	grade 3	28766	HUH23.979	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE		Metastasis Hepar		Tinggi	IV	negatif	negatif	negatif
17	SN	30	Pre menopause	grade 2	208149	HUH 23.769	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	II B	negatif	negatif	positif

18	AB	59	post menopause	grade 2	208273	HUH.23.915	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE		Metastasis Hepar		Tinggi	IV	positif	positif	positif
19	AP	56	post menopause	grade 3	182881	HUH.23.883	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIB	negatif	negatif	positif
20	GI	43	Pre menopause	grade 3	207374	HUH23.861	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIA	negatif	negatif	negatif
21	SL	60	post menopause	grade 3	204265	HUH.23.788	ADENOCARCINOMA MUSINOSUM,	Metastasis paru	Metastasis Hepar		Tinggi	IV	negatif	negatif	positif
22	HA	44	Pre menopause	Grade 1	203881	HUH 23.717	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE, LVSI NEGATIF	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	negatif
23	NI	54	post menopause	Grade 2	205649	HUH24.018	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE			Metastasis Otak	Tinggi	IV	positif	positif	negatif
24	NR	66	post menopause	Grade 2	123876	HUH.23.79	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	negatif	negatif
25	AN	67	post menopause	Grade 2	192251	HUH.23.34	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE		Metastasis Hepar		Tinggi	IV	positif	positif	negatif
26	RF	40	Pre menopause	Grade 1	210969	HUH.2.1208	INVASIVE PAPILER CARCINOMA	Tidak Metastasis	Tidak Metastasis		Tinggi	IIA	positif	positif	negatif
27	ST	50	Pre menopause	grade 1	207229	HUH.23.906	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	positif	positif
28	JE	61	post menopause	grade 3	217920	HUH.23.330	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	positif	positif	negatif
29	IN	40	Pre menopause	Grade 2	190937	HUH.23.1440	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE DENGAN MILLER PAYNE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	negatif	negatif	positif
30	MT	70	post menopause	grade 2	201794	HUH.23.894	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	negatif	negatif	negatif
31	NR	42	Pre menopause	grade 3	184213	HUH.23.134	INVASIVE PAPILLARY CARCINOMA MAMMAE	Metastasis paru			Tinggi	IV	positif	positif	positif
32	SF	57	post menopause	grade 2	200340	HUH.23.167	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	positif	positif	negatif
33	MR	60	post menopause	grade 2	212350	HUH.23.1251	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIB	positif	positif	negatif
34	SK	71	post menopause	grade 3	208143	HUH.23.941	INVASIVE PAPILLARY CARCINOMA MAMMAE	Metastasis paru			Tinggi	IV	positif	negatif	negatif
35	AR	39	Pre menopause	grade 2	209896	HUH.23.1099	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	positif	positif	negatif
36	AS	57	post menopause	grade 3	203999	HUH.23.565	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	negatif	negatif	positif
37	SM	59	post menopause	grade 2	190682	HUH22.1319	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE		Metastasis Hepar		Tinggi	IV	positif	positif	negatif

38	HH	49	Pre menopause	grade 2	190587	HUH22.1321	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	negatif	negatif	positif
39	MN	68	post menopause	grade 3	204698	HUH22.1294	INVASIVE BREAST CARCINOMA	Metastasis paru			Tinggi	IV	positif	positif	positif
40	RR	51	Pre menopause	grade 1	83860	HUH22.1246	INVASIVE PAPILLARY CARCINOMA MAMMAE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	positif	negatif
41	KT	62	post menopause	grade 2	188615	HUH22.1248	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	negatif	negatif	positif
42	AD	57	post menopause	Grade 2	30145	HUH22.1255	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru		Metastasis tulang	Tinggi	IV	negatif	negatif	negatif
43	SG	63	post menopause	grade 3	77742	HUH22.1195	MUCINOUS CARCINOMA MAMMAE	Metastasis paru			Tinggi	IV	negatif	negatif	positif
44	BS	73	post menopause	grade 2	185418	HUH22.949	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	negatif
45	MW	39	Pre menopause	grade 2	182963	HUH22.953	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIB	positif	positif	negatif
46	RB	63	post menopause	grade 1	183171	HUH22.920	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	positif	negatif
47	WH	38	Pre menopause	grade 2	182963	HUH22.799	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIB	positif	positif	negatif
48	FM	37	Pre menopause	grade 1	183095	HUH22.784	INVASIVE PAPILLARY CARCINOMA MAMMAE	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	negatif
49	AN	72	post menopause	grade 1	216518	HUH24.385	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	positif	negatif
50	NM	55	post menopause	grade 1	214398	HUH24.398	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	positif	positif
51	SS	57	post menopause	grade 2	219108	HUH24.343	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	positif	Positif
52	KI	35	Pre menopause	grade 3	218110	HUH24.404	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIIB	positif	positif	positif
53	AA	42	Pre menopause	grade 3	27333	HUH24.827	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	negatif
54	ME	49	Pre menopause	grade 3	224248	HUH24.846	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIB	negatif	negatif	negatif
55	BH	71	post menopause	grade 2	128355	HUH24.1012	MUCINOUS CARCINOMA MAMMAE	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	negatif
56	RL	50	Pre menopause	grade 2	225772	HUH24.977	INVASIVE LOBULAR CARCINOMA	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	negatif
57	IP	39	Pre menopause	grade 2	74134	HUH24.1010	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIA	positif	positif	positif
58	FR	50	Pre menopause	grade 1	225384	HUH24.1286	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIB	positif	positif	negatif
59	HL	72	post menopause	grade 3	207004	HUH24.1245	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIB	negatif	negatif	positif
60	JM	60	post menopause	grade 2	228969	HUH24.1293	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Rendah	IIB	positif	positif	positif
61	YT	68	post menopause	grade 3	231659	HUH24.1652	INVASIVE LOBULAR CARCINOMA	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIB	positif	positif	negatif

62	NA	48	Pre menopause	grade 3	227544	HUH24.1658	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIA	negatif	negatif	negatif
63	JU	61	post menopause	grade 3	227585	HUH24.1078	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIB	negatif	negatif	negatif
64	IM	47	Pre menopause	grade 3	225215	HUH24.939	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE, WHO GRADE III	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIB	positif	positif	negatif
65	HM	52	Pre menopause	grade 3	225024	HUH24.966	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIB	negatif	negatif	positif
66	IM	44	Pre menopause	grade 2	231953	HUH24.1597	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	METASTASIS PARU			Tinggi	IV	positif	positif	positif
67	VD	41	Pre menopause	grade 2	225004	HUH24.950	INVASIVE LOBULAR CARCINOMA (PLEOMORFIK PATTERN)	Tidak Metastasis	Tidak Metastasis		Tinggi	IIIB	positif	positif	Positif
68	SM	61	post menopause	grade 2	190682		INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE		Metastasis Hepar		Tinggi	IV	positif	negatif	negatif
69	NA	54	post menopause	grade 3	224137	IHC.UH.24.094	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE	Metastasis paru			Tinggi	IV	positif	positif	negatif
70	YD	40	Pre menopause	grade 2	217169	IHC.UH.24.005	INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE		Metastasis Hepar		Tinggi	IV	negatif	negatif	positif
71	SA	40	Pre menopause	grade 2	230925	IHC.UH.24.173	INVASIVE LOBULAR CARCINOMA		Metastasis Hepar		Tinggi	IV	negatif	negatif	positif

Lampiran 4

Frequencies

		Umur Pasien	Klasifikasi Umur	Status Menopause	Stadium	Status Metastasis	Jenis Metastasis	Jenis Histopatologi	Grading Histopatologi	Status ER	Status PR	Status HER2 Neu	Ekspresi TAM
N	Valid	71	71	71	71	71	30	71	71	71	71	71	71
	Missing	0	0	0	0	0	41	0	0	0	0	0	0

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
Umur Pasien	71	100.0%	0	0.0%	71	100.0%

Descriptives

			Statistic	Std. Error
Umur Pasien	Mean		52.3803	1.31657
	95% Confidence Interval for Mean	Lower Bound	49.7545	
		Upper Bound	55.0061	
	5% Trimmed Mean		52.3271	
	Median		52.0000	
	Variance		123.068	
	Std. Deviation		11.09358	
	Minimum		30.00	
	Maximum		73.00	
	Range		43.00	
	Interquartile Range		19.00	
	Skewness		.075	.285
	Kurtosis		-.987	.563

Ekspresi TAM * Status Metastasis Crosstabulation

			Status Metastasis		
			Metastasis	Tidak Metastasis	Total
Ekspresi TAM	Ekspresi TAM Tinggi	Count	27	15	42
		% within Ekspresi TAM	64.3%	35.7%	100.0%
		% within Status Metastasis	90.0%	36.6%	59.2%
		% of Total	38.0%	21.1%	59.2%
	Ekspresi TAM Rendah	Count	3	26	29
		% within Ekspresi TAM	10.3%	89.7%	100.0%
		% within Status Metastasis	10.0%	63.4%	40.8%
		% of Total	4.2%	36.6%	40.8%
Total		Count	30	41	71
		% within Ekspresi TAM	42.3%	57.7%	100.0%
		% within Status Metastasis	100.0%	100.0%	100.0%
		% of Total	42.3%	57.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	20.457[a]	1	.000		
Continuity Correction[b]	18.306	1	.000		
Likelihood Ratio	22.678	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	20.169	1	.000		
N of Valid Cases	71				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 12.25.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Ekspresi TAM (Ekspresi TAM Tinggi / Ekspresi TAM Rendah)	15.600	4.038	60.267
For cohort Status Metastasis = Metastasis	6.214	2.079	18.574
For cohort Status Metastasis = Tidak Metastasis	.398	.261	.609
N of Valid Cases	71		

Ekspresi TAM * Grading_Histopatologi Crosstabulation

			Grading_Histopatologi		
			Grade III	Grade I-II	Total
Ekspresi TAM	Ekspresi TAM Tinggi	Count	23	19	42
		% within Ekspresi TAM	54.8%	45.2%	100.0%
		% within Grading_Histopatologi	88.5%	42.2%	59.2%
		% of Total	32.4%	26.8%	59.2%
	Ekspresi TAM Rendah	Count	3	26	29
		% within Ekspresi TAM	10.3%	89.7%	100.0%
		% within Grading_Histopatologi	11.5%	57.8%	40.8%
		% of Total	4.2%	36.6%	40.8%
Total		Count	26	45	71
		% within Ekspresi TAM	36.6%	63.4%	100.0%
		% within Grading_Histopatologi	100.0%	100.0%	100.0%
		% of Total	36.6%	63.4%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	14.582[a]	1	.000		
Continuity Correction[b]	12.731	1	.000		
Likelihood Ratio	16.147	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	14.377	1	.000		
N of Valid Cases	71				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 10.62.

b. Computed only for a 2x2 table

Risk Estimate

		95% Confidence Interval	
	Value	Lower	Upper
Odds Ratio for Ekspresi TAM (Ekspresi TAM Tinggi / Ekspresi TAM Rendah)	10.491	2.745	40.094
For cohort Grading_Histopatologi = Grade III	5.294	1.751	16.001
For cohort Grading_Histopatologi = Grade I-II	.505	.354	.720
N of Valid Cases	71		

Ekspresi TAM * Status Hormonal Reseptor Crosstabulation

			Status Hormonal Reseptor		
			HR Negatif	HR Positif	Total
Ekspresi TAM	Ekspresi TAM Tinggi	Count	23	19	42
		% within Ekspresi TAM	54.8%	45.2%	100.0%
		% within Status Hormonal Reseptor	85.2%	43.2%	59.2%
		% of Total	32.4%	26.8%	59.2%
	Ekspresi TAM Rendah	Count	4	25	29
		% within Ekspresi TAM	13.8%	86.2%	100.0%
		% within Status Hormonal Reseptor	14.8%	56.8%	40.8%
		% of Total	5.6%	35.2%	40.8%
Total		Count	27	44	71
		% within Ekspresi TAM	38.0%	62.0%	100.0%
		% within Status Hormonal Reseptor	100.0%	100.0%	100.0%
		% of Total	38.0%	62.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	12.218[a]	1	.000		
Continuity Correction[b]	10.541	1	.001		
Likelihood Ratio	13.205	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	12.046	1	.001		
N of Valid Cases	71				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 11.03.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Ekspresi TAM (Ekspresi TAM Tinggi / Ekspresi TAM Rendah)	7.566	2.238	25.572
For cohort Status Hormonal Reseptor = HR Negatif	3.970	1.535	10.271
For cohort Status Hormonal Reseptor = HR Positif	.525	.365	.755

N of Valid Cases	71		

Ekspresi TAM * Subtipe Molekuler 3 Crosstabulation

			Subtipe Molekuler 3			
			Luminal	HER2 Type	TNBC	Total
Ekspresi TAM	Ekspresi TAM Tinggi	Count	19	16	7	42
		% within Ekspresi TAM	45.2%	38.1%	16.7%	100.0%
		% within Subtipe Molekuler 3	43.2%	84.2%	87.5%	59.2%
		% of Total	26.8%	22.5%	9.9%	59.2%
	Ekspresi TAM Rendah	Count	25	3	1	29
		% within Ekspresi TAM	86.2%	10.3%	3.4%	100.0%
		% within Subtipe Molekuler 3	56.8%	15.8%	12.5%	40.8%
		% of Total	35.2%	4.2%	1.4%	40.8%
Total		Count	44	19	8	71
		% within Ekspresi TAM	62.0%	26.8%	11.3%	100.0%
		% within Subtipe Molekuler 3	100.0%	100.0%	100.0%	100.0%
		% of Total	62.0%	26.8%	11.3%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	12.243[a]	2	.002
Likelihood Ratio	13.254	2	.001
Linear-by-Linear Association	10.448	1	.001
N of Valid Cases	71		

a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 3.27.

Ranks

	Ekspresi TAM	N	Mean Rank	Sum of Ranks
Subtipe Molekuler 3	Ekspresi TAM Tinggi	42	42.00	1764.00
	Ekspresi TAM Rendah	29	27.31	792.00
	Total	71		

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.947[a]	1	.163		
Continuity Correction[b]	1.331	1	.249		
Likelihood Ratio	1.961	1	.161		
Fisher's Exact Test				.227	.124
Linear-by-Linear Association	1.920	1	.166		
N of Valid Cases	71				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 13.89.

b. Computed only for a 2x2 table